Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-02
2007-10-02
Spector, Lorraine (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S192100, C424S236100, C424S247100, C424S198100
Reexamination Certificate
active
10831435
ABSTRACT:
Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.
REFERENCES:
patent: 5919665 (1999-07-01), Williams et al.
patent: WO91/00725 (1991-01-01), None
patent: WO91/99725 (1991-01-01), None
patent: WO 95/32738 (1995-12-01), None
patent: WO95/32738 (1995-12-01), None
patent: WO96/33273 (1996-10-01), None
patent: WO 96/33273 (1996-10-01), None
patent: WO98/07864 (1998-02-01), None
patent: WO 98/07864 (1998-02-01), None
Gaisano et al. 1994. J Biol Chem 269:17062-17066.
Gaisano et al. 1998. Gastroenterology 114:A460-A461.
Sandvig et al. 2004. Int J Med Microbiol. 293:483-490.
Pohl et al. 1997. J Biol Chem. 272:18179-18184.
Dangl et al. 1988. EMBO J. 7:1989-1994.
Kreis, et al, Neuroscience Letters 230:89-92, 1997.
Gaisano et al, J. of Biol. Chem. 269:17062-17066, 1994.
Scheele et al, Gastroenterology 92(2)345-353, 1987.
Dangl et al. EMBO HJ. 7(7):1989-94, 1988.
Skonick et al, Trends in Biotechnology 18 (1): 34-39, Jan. 2000.
Gaisano et al, Gastroenterology 111: 1661-1169, Dec. 1996. Accompanying Editorial: Jamieson, Gastroenterology 111-1171-1172, Dec. 1996.
Ganong, W.F., In: Review of Medical Physiology, 17thEdition. Lange Medical Publications, East Norwal, Connecticut, p. 446.
Tani et al, “Effect of a New Cholecystokinin Receptor Antagonist Loxiglumide on Acute Pancreatitis in Two Experimental Animal Models”, Pancreas 5: pp. 284-290 (1990).
Rizo et al, “Mechanics of membrane fusion”, Nature Structural Biology 5: pp. 839-842 (Oct. 1998).
Niemann et al, “Clostridial neurotoxins: new tools for dissecting exocytosis”, Trends in Cell Biology 4: pp. 179-185(May 1994).
Coffield et al, “The Site and Mechanism of Action of Botulinum Neurotoxin in Therapy with Botulinum Toxin”, Neurological Disease and Therapy, Therapy with Botulinum Toxin, pp. 3-13 (1994).
Tonello et al, “Tetanus and Botulism Neurotoxins in Intracellular Protein Catabolism”, Adv. Exp. Med. Biol. 389, pp. 251-260 (1996).
Sharma et al, “Hemagglutinin Binding Mediated Protection of Botulinum Neurotoxin From Proteolysis”, Journal of Natural Toxins 7: pp. 239-253(1998).
Kennedy et al, Identification of Two Amino Acids of the Human Cholecystokinin-A Receptor That Interact with the N-terminal Moiety of Cholecystokinin, The Journal of Biological Chemistry, 272: pp. 2920-2926 (1997).
Pohl et al, “Ligand-induced Internalization of Cholecystokinin Receptors”, The Journal of Biological Chemistry 272: pp. 18179-18184 (1997).
Ji et al, “Direct Indentification of a Distinct Site of Interaction between the Carboxyl-terminal Residue of Cholecystokinin and the Type A Cholecystokinin Receptor Using Photoaffinity Labeling”, The Journal of Biological Chemistry 272, pp. 24393-24401 (1997).
Jagerschmidt et al, “Mutation of Asp100in the Second Transmembrane Domain of the Cholecystokinin B Receptor Increases Antagonist Binding and Reduces Signal Transduction”,Molecular Pharmacology 48: pp. 783-789(1995).
Zhou et al, “Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxicity after Reconstitution with the Heavy Chain, Biochemistry” 34: pp. 15175-15181 (1995).
Kurazono et al, “Minimal Essential Domains Specifying Toxicity of the Light Chains of Tetanus Toxin and Botulinum Neurotoxin Type A*”, The Journal of Biological Chemistry, pp. 14721-14729 (1992).
Oblatt-Montal et al, “Formation of ion channels in lipid bilayers by a peptide with the predicted transmembrane sequence of botulinum neurotoxin A”, Protein Science, vol. 4: pp. 1490-1497(1995).
Ulrich et al, “Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor”, Gen Bank 416772, Web Site ncbi.nlm.nih.gov.
Binz et al, “The complete sequence of the botulinum type A neurotoxin and its comparison with other Clostridial neurotoxins”, Gen Bank M30196, Web Site ncbi.nlm.nih.gov.
Sharma et al, “Functional role of Hn-33: Enhanced cleavage of synaptic protein SNAP-25 by botulinum neutoxin A and E”; Book of Abstracts, 216.
Fujita-Yoshigaki et al, “Vesicle-associated Membrane Protein 2 Is Essential for cAMP-regulated Exocytosis in Rat Parotid Acinar Cells”; The Journal of Biological Chemistry, vol. 271,No. 22,Issue of May 31,pp. 13130-13134.
Binz et al, “The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins”; The Journal of Biological Chemistry, vol. 265,No. 16, Issue of Jun. 5, pp. 9153-9158.
Ulrich et al, “Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor”,Biochemical&Biophysical Research Comm., vol. 193, No. 1, 1993, May 28, 1993,pp. 204-211.
Binz et al, “The complete sequence of the botulinum type A neurotoxin and its comparison with other Clostridial neurotoxins”, The Journal of Biological Chemistry, vol. 265,No. 16,Issue of Jun. 5,pp. 9153-9158, 1990.
Sharma et al, “Functional role of HN-33: Enhanced cleavage of synaptic protein SNAP-25 by botulinum neurotoxin A and E”; Book of Abstracts, 216, 2006.
Aoki Kei Roger
Sachs George
Allergan Inc.
German Joel B.
Shafer Shulamith H
Spector Lorraine
Stathakis Dean G.
LandOfFree
Methods and compositions for the treatment of pancreatitis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of pancreatitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of pancreatitis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3896011